Ginkgo Bioworks Holdings Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
DNA$12.37+9.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except per share data)
| As of September 30, 2024 | As of December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $616,214 | $944,073 |
| Accounts receivable, net | 23,411 | 17,157 |
| Accounts receivable - related parties | 531 | 742 |
| Prepaid expenses and other current assets | 22,324 | 39,777 |
| Total current assets | 662,480 | 1,001,749 |
| Property, plant, and equipment, net | 211,035 | 188,193 |
| Operating lease right-of-use assets | 405,911 | 206,801 |
| Investments | 62,103 | 78,565 |
| Intangible assets, net | 79,566 | 82,741 |
| Goodwill | — | 49,238 |
| Other non-current assets | 59,788 | 58,055 |
| Total assets | $1,480,883 | $1,665,342 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $15,700 | $9,323 |
| Deferred revenue (includes $1,434 and $5,426 from related parties) | 22,894 | 44,486 |
| Accrued expenses and other current liabilities | 75,833 | 110,051 |
| Total current liabilities | 114,427 | 163,860 |
| Non-current liabilities: | ||
| Deferred revenue, net of current portion (includes $72,186 and $119,053 from related parties) | 105,247 | 158,062 |
| Operating lease liabilities, non-current | 445,592 | 221,835 |
| Other non-current liabilities | 17,674 | 24,433 |
| Total liabilities | 682,940 | 568,190 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 200,000 shares authorized; none issued | — | — |
| Common stock, $0.0001 par value (Note 7) | 5 | 5 |
| Additional paid-in capital | 6,527,698 | 6,386,191 |
| Accumulated deficit | (5,730,023) | (5,290,528) |
| Accumulated other comprehensive income | 263 | 1,484 |
| Total stockholders’ equity | 797,943 | 1,097,152 |
| Total liabilities and stockholders’ equity | $1,480,883 | $1,665,342 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.